Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus XIMINO.
FORBAXIN vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
IV: 500 mg every 12 hours, infused over 30 minutes.
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60-70% unchanged), biliary/fecal (20-30%)
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category C
Category C
Antibiotic
Antibiotic